SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "(L773:1538 7755) "

Search: (L773:1538 7755)

  • Result 1-10 of 415
Sort/group result
   
EnumerationReferenceCoverFind
1.
  •  
2.
  • Adami, HO, et al. (author)
  • Ranitidine Use and Risk of Upper Gastrointestinal Cancers
  • 2021
  • In: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. - 1538-7755. ; 30:12, s. 2302-2308
  • Journal article (peer-reviewed)
  •  
3.
  • Adami, HO, et al. (author)
  • Ranitidine Use and Risk of Upper Gastrointestinal Cancers-Reply
  • 2022
  • In: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. - 1538-7755. ; 31:4, s. 915-915
  • Journal article (other academic/artistic)
  •  
4.
  • Adams, Charleen, et al. (author)
  • Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study
  • 2019
  • In: Cancer Epidemiology, Biomarkers and Prevention. - : American Association for Cancer Research (AACR). - 1055-9965 .- 1538-7755. ; 28:1, s. 208-216
  • Journal article (peer-reviewed)abstract
    • BACKGROUND: Whether associations between circulating metabolites and prostate cancer are causal is unknown. We report on the largest study of metabolites and prostate cancer (2,291 cases and 2,661 controls) and appraise causality for a subset of the prostate cancer-metabolite associations using two-sample Mendelian randomization (MR).MATERIALS AND METHODS: The case-control portion of the study was conducted in nine UK centres with men aged 50-69 years who underwent prostate-specific antigen (PSA) screening for prostate cancer within the Prostate testing for cancer and Treatment (ProtecT) trial. Two data sources were used to appraise causality: a genome-wide association study (GWAS) of metabolites in 24,925 participants and a GWAS of prostate cancer in 44,825 cases and 27,904 controls within the Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium.RESULTS: Thirty-five metabolites were strongly associated with prostate cancer (p <0.0014, multiple-testing threshold). These fell into four classes: i) lipids and lipoprotein subclass characteristics (total cholesterol and ratios, cholesterol esters and ratios, free cholesterol and ratios, phospholipids and ratios, and triglyceride ratios); ii) fatty acids and ratios; iii) amino acids; iv) and fluid balance. Fourteen top metabolites were proxied by genetic variables, but MR indicated these were not causal.CONCLUSIONS: We identified 35 circulating metabolites associated with prostate cancer presence, but found no evidence of causality for those 14 testable with MR. Thus, the 14 MR-tested metabolites are unlikely to be mechanistically important in prostate cancer risk.IMPACT: The metabolome provides a promising set of biomarkers that may aid prostate cancer classification.
  •  
5.
  • Aglago, Elom K., et al. (author)
  • Soluble Receptor for Advanced Glycation End-products (sRAGE) and Colorectal Cancer Risk : A Case-Control Study Nested within a European Prospective Cohort
  • 2021
  • In: Cancer Epidemiology, Biomarkers and Prevention. - : American Association for Cancer Research. - 1055-9965 .- 1538-7755. ; 30:1, s. 182-192
  • Journal article (peer-reviewed)abstract
    • BACKGROUND: Overexpression of the receptor for advanced glycation end-product (RAGE) has been associated with chronic inflammation, which in turn has been associated with increased colorectal cancer risk. Soluble RAGE (sRAGE) competes with RAGE to bind its ligands, thus potentially preventing RAGE-induced inflammation.METHODS: To investigate whether sRAGE and related genetic variants are associated with colorectal cancer risk, we conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC). Plasma sRAGE concentrations were measured by ELISA in 1,361 colorectal cancer matched case-control sets. Twenty-four SNPs encoded in the genes associated with sRAGE concentrations were available for 1,985 colorectal cancer cases and 2,220 controls. Multivariable adjusted ORs and 95% confidence intervals (CIs) were computed using conditional and unconditional logistic regression for colorectal cancer risk and circulating sRAGE and SNPs, respectively.RESULTS: Higher sRAGE concentrations were inversely associated with colorectal cancer (ORQ5vs.Q1, 0.77; 95% CI, 0.59-1.00). Sex-specific analyses revealed that the observed inverse risk association was restricted to men (ORQ5vs.Q1, 0.63; 95% CI, 0.42-0.94), whereas no association was observed in women (ORQ5vs.Q1, 1.00; 95% CI, 0.68-1.48; Pheterogeneity for sex = 0.006). Participants carrying minor allele of rs653765 (promoter region of ADAM10) had lower colorectal cancer risk (C vs. T, OR, 0.90; 95% CI, 0.82-0.99).CONCLUSIONS: Prediagnostic sRAGE concentrations were inversely associated with colorectal cancer risk in men, but not in women. An SNP located within ADAM10 gene, pertaining to RAGE shedding, was associated with colorectal cancer risk.IMPACT: Further studies are needed to confirm our observed sex difference in the association and better explore the potential involvement of genetic variants of sRAGE in colorectal cancer development.
  •  
6.
  •  
7.
  • Agudo, Antonio, et al. (author)
  • Polymorphisms in metabolic genes related to tobacco smoke and the risk of gastric cancer in the European prospective investigation into cancer and nutrition
  • 2006
  • In: Cancer Epidemiology Biomarkers & Prevention. - 1538-7755. ; 15:12, s. 2427-2434
  • Journal article (peer-reviewed)abstract
    • Metabolizing enzymes, which often display genetic polymorphisms, are involved in the activation of compounds present in tobacco smoke that may be relevant to gastric carcinogenesis. We report the results of a study looking at the association between risk of gastric adenocarcinoma and polymorphisms in genes CYP1A1, CYP1A2, EPHX1, and GSTT1. A nested case-control study was carried out within the European Prospective Investigation into Cancer and Nutrition, developed in 10 European countries. The study includes 243 newly diagnosed cases of histologically confirmed gastric adenocarcinoma and 946 controls matched by center, age, sex, and date of blood collection. Genotypes were determined in nuclear DNA from WBCs. We found an increased risk of gastric cancer for homozygotes for C (histidine) variant in Y113H of EPHX1 (odds ratio, 1.91; 95% confidence interval, 1.19-3.07) compared with subjects with TC/TT. There was also a significant increased risk for smokers carrying at least one variant allele A in Ex7+129C > A (m4) of CYP1A1 and never smokers with null GSTT1 and allele A in the locus -3859G > A of CYP1A2. Most of these genes are involved in the activation and detoxification of polycyclic aromatic hydrocarbons, suggesting a potential role of these compounds in gastric carcinogenesis.
  •  
8.
  • Ahlin, Cecilia, et al. (author)
  • Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer
  • 2009
  • In: Cancer Epidemiology, Biomarkers and Prevention. - 1055-9965 .- 1538-7755. ; 18:9, s. 2501-2506
  • Journal article (peer-reviewed)abstract
    • Background: Proliferative markers are not recommended as prognostic   factors for clinical use in breast cancer due to lack of   standardization in methodology. However, proliferation is driving   several gene expression signatures emphasizing the need for a reliable   proliferative marker IF or clinical use. Studies suggest that cyclin A   is a prognostic marker with satisfying reproducibility. We investigated   cyclin A as a prognostic marker in node-negative breast cancer using   previously defined cutoff values.   Patients and Methods: In a case-control study, we defined 190 women who   died from breast cancer as cases and 190 women alive at the time for   the corresponding case's death as controls. Inclusion criteria were   tumor size <= 50 mm, no lymph node metastases and no adjuvant   chemotherapy. Tumor tissues were immunostained for cyclin A using   commercially available antibodies.   Results: We found a statistically significant association between   expression of cyclin A and breast cancer death in a univariate model:   odds ratio for cyclin A(ave) 2.7 [95% confidence interval (CI),   1.7-4.3] and cyclin A(max) 3.4 (CI, 2.1-5.5). Corresponding odds ratio   for Ki67 were Ki67(ave) 1.9 (CI, 1.2-3.1) and Ki67(max) 1.7 (CI,   1.1-2.7) and for grade 3.1 (CI, 1.8-5.1). Cyclin A was strongly   correlated to Ki67 and grade why a model including all was not   appropriate.   Conclusions: Cyclin A is a prognostic factor for breast cancer death in   node-negative patients using standardized methodology regarding scoring   and cutoff values. Adding cyclin A as a proliferative marker to established clinicopathologic factors will improve the separation of  low and high risk breast cancer.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-10 of 415
Type of publication
journal article (411)
research review (4)
Type of content
peer-reviewed (408)
other academic/artistic (7)
Author/Editor
Riboli, Elio (66)
Kaaks, Rudolf (65)
Tumino, Rosario (65)
Overvad, Kim (60)
Trichopoulou, Antoni ... (56)
Boeing, Heiner (55)
show more...
Khaw, Kay-Tee (50)
Palli, Domenico (47)
Weiderpass, Elisabet ... (44)
Boutron-Ruault, Mari ... (43)
Bueno-de-Mesquita, H ... (40)
Vineis, Paolo (38)
Panico, Salvatore (37)
Sánchez, Maria-José (36)
Clavel-Chapelon, Fra ... (35)
Wolk, Alicja (35)
Trichopoulos, Dimitr ... (35)
Tjønneland, Anne (33)
Tjonneland, Anne (33)
Ardanaz, Eva (31)
Jenab, Mazda (31)
Peeters, Petra H. M. (30)
Gunter, Marc J. (29)
Barricarte, Aurelio (27)
Lund, Eiliv (26)
Olsen, Anja (26)
Hallmans, Göran (26)
Manjer, Jonas (25)
Dorronsoro, Miren (25)
Johansson, Mattias (23)
Adami, Hans Olov (22)
Sacerdote, Carlotta (21)
Stattin, Pär (21)
Travis, Ruth C (21)
Allen, Naomi E (21)
Linseisen, Jakob (20)
Adami, HO (20)
van Guelpen, Bethany (20)
Rinaldi, Sabina (20)
Ferrari, Pietro (20)
Navarro, Carmen (20)
Skeie, Guri (19)
Gram, Inger T. (19)
Lagiou, Pagona (19)
Bingham, Sheila (19)
Mucci, LA (19)
Dossus, Laure (19)
Krogh, Vittorio (18)
Mattiello, Amalia (18)
Dillner, Joakim (18)
show less...
University
Karolinska Institutet (262)
Umeå University (138)
Lund University (124)
Uppsala University (87)
Örebro University (23)
University of Gothenburg (12)
show more...
Linköping University (9)
Mälardalen University (7)
Stockholm University (3)
Malmö University (3)
Kristianstad University College (1)
Royal Institute of Technology (1)
Jönköping University (1)
Chalmers University of Technology (1)
The Swedish School of Sport and Health Sciences (1)
show less...
Language
English (414)
Undefined language (1)
Research subject (UKÄ/SCB)
Medical and Health Sciences (266)
Agricultural Sciences (2)
Natural sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view